Fang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fang Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Chao Lin
The Institute for Advanced Materials and Nano Biomedicine, Tongji University, Shanghai 200092, P.R. China
3 shared publicationsDonglu Shi
The Institute for Advanced Materials and Nano Biomedicine, Tongji University, Shanghai 200072, China
2 shared publicationsFanfei Kong
Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publicationsHuaishi Zhu
Department of Radiology, Huangpu District Central Hospital, Shanghai 200002, P.R. China
2 shared publications- Jing Sun
Department of Minimally Invasive Gynecologic Surgery, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications Qiujie Ba
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, 200040, PR China
2 shared publications
Latest Publications
- 1 November 2014
- Published by Elsevier in Cancer Letters
- Vol. 354 (2) , 398-406
AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo
- 1 November 2014
- Published by Elsevier in Cancer Letters
- Vol. 354 (2) , 398-406
AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo
- 1 October 2012
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 32 (7) , 2017-2025
In-situ forming biodegradable glycol chitosan-based hydrogels: Synthesis, characterization, and chondrocyte culture
- 1 October 2012
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 32 (7) , 2017-2025
In-situ forming biodegradable glycol chitosan-based hydrogels: Synthesis, characterization, and chondrocyte culture
- 20 September 2012
- Published by Spandidos Publications in Oncology Letters
- Vol. 4 (6) , 1254-1258
In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus
Retroviruses encoding the TNF-related apoptosis-inducing ligand (TRAIL) gene were generated by transient transfection of the retrovirus packing cell line BOSC 23 using TRAIL-encoding plasmid. The retrovirus was able to transduce drug-resistant A2780/DDP ovarian carcinoma cells in vitro and induce TRAIL expression in the cells, as detected by western blot assay. Furthermore, the TRAIL protein led to the growth inhibition of the cells via a caspase-activated apoptotic mechanism. It was confirmed that exposure of such cells to cisplatin in combination with the TRAIL-encoding retrovirus resulted in higher anticancer activity in vitro and in the xenograft A2780/DDP tumor in a nude mouse model. This study suggests that chemotherapy in combination with TRAIL gene therapy may be an efficient approach to treat drug-resistant ovarian cancer.
- 20 September 2012
- Published by Spandidos Publications in Oncology Letters
- Vol. 4 (6) , 1254-1258
In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus
Retroviruses encoding the TNF-related apoptosis-inducing ligand (TRAIL) gene were generated by transient transfection of the retrovirus packing cell line BOSC 23 using TRAIL-encoding plasmid. The retrovirus was able to transduce drug-resistant A2780/DDP ovarian carcinoma cells in vitro and induce TRAIL expression in the cells, as detected by western blot assay. Furthermore, the TRAIL protein led to the growth inhibition of the cells via a caspase-activated apoptotic mechanism. It was confirmed that exposure of such cells to cisplatin in combination with the TRAIL-encoding retrovirus resulted in higher anticancer activity in vitro and in the xenograft A2780/DDP tumor in a nude mouse model. This study suggests that chemotherapy in combination with TRAIL gene therapy may be an efficient approach to treat drug-resistant ovarian cancer.
- 1 November 2011
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 88 (1) , 58-62
Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin
- 1 November 2011
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 88 (1) , 58-62
Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin
- 1 May 2010
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 17 (5) , 585-590
Ribosome Display and Selection of Human Anti-Placental Growth Factor scFv Derived from Ovarian Cancer Patients
Ribosome display is a powerful cell-free technology to select a desired antibody together with its encoding mRNA. In this study, a human single-chain variable fragment (scFv) library was generated from the peripheral blood lymphocyte RNA of 10 ovarian cancer patients and then panned against bead-conjugated human PlGF, a protein that may contribute to the growth and metastasis of ovarian cancer. A selected scFv antibody was evaluated by Western blot and its affinity constant to the PlGF was determined by noncompetitive enzyme immunoassay. This study highlights the ribosomal display technology for the selection of human antibody from patient-derived gene pools.
- 1 May 2010
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 17 (5) , 585-590
Ribosome Display and Selection of Human Anti-Placental Growth Factor scFv Derived from Ovarian Cancer Patients
Ribosome display is a powerful cell-free technology to select a desired antibody together with its encoding mRNA. In this study, a human single-chain variable fragment (scFv) library was generated from the peripheral blood lymphocyte RNA of 10 ovarian cancer patients and then panned against bead-conjugated human PlGF, a protein that may contribute to the growth and metastasis of ovarian cancer. A selected scFv antibody was evaluated by Western blot and its affinity constant to the PlGF was determined by noncompetitive enzyme immunoassay. This study highlights the ribosomal display technology for the selection of human antibody from patient-derived gene pools.